IL17A and metabolic dysfunction-associated steatotic liver disease: In addition, preventing CXCR3-dependent hepatic Th17 accrual and blocking IL-17A signaling using neutralizing antibodies both alleviated nonalcoholic fatty liver disease (NAFLD) (15, 16), suggesting an important contribution of hepatic Th17 cells to NAFLD severity.